{"id":43315,"date":"2020-07-21T22:10:47","date_gmt":"2020-07-21T20:10:47","guid":{"rendered":"https:\/\/newserver.fyb.de\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/"},"modified":"2020-07-21T22:10:47","modified_gmt":"2020-07-21T20:10:47","slug":"tubulis-e10-7-million-series-a-financing-from-prominent-investors","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/","title":{"rendered":"Tubulis: \u20ac10.7 million Series A financing from prominent investors"},"content":{"rendered":"

Munich, Germany \u2014 Tubu\u00adlis<\/strong> today announ\u00adced the closing of a \u20ac10.7 million Series A finan\u00adcing round. This is inten\u00added to drive the deve\u00adlo\u00adp\u00adment of a new class of highly stable and potent Anti\u00adbody Drug Conju\u00adga\u00adtes (ADCs, \u201canti\u00adbody-drug conju\u00adga\u00adtes\u201d) and to support the further growth of the company. Tubu\u00adlis closes \u20ac10.7M Series A finan\u00adcing was led jointly by BioMed\u00adPart\u00adners<\/strong> and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF)<\/strong> with addi\u00adtio\u00adnal parti\u00adci\u00adpa\u00adtion from Seven\u00adture Part\u00adners<\/strong>, copa\u00adrion, Bayern Kapi\u00adtal <\/strong>and OCCIDENT<\/strong> as well as high net worth indi\u00advi\u00addu\u00adals<\/strong> and the founders.<\/p>\n

Tubu\u00adlis is a spin-off company that emer\u00adged in 2019 from the Leib\u00adniz Rese\u00adarch Insti\u00adtute Berlin (FMP) and Ludwig Maxi\u00admi\u00adlian Univer\u00adsity (LMU) Munich to realize the thera\u00adpeu\u00adtic poten\u00adtial of ADCs for the treat\u00adment of cancer and other diseases.<\/p>\n

\u201cTubu\u00adlis\u2019 goal is to use our dual plat\u00adform to deve\u00adlop ADCs that are perfectly matched to the dise\u00adase in ques\u00adtion. Funding from such an expe\u00adri\u00aden\u00adced consor\u00adtium is further vali\u00adda\u00adtion of our tech\u00adno\u00adlogy and reflects the current renais\u00adsance that the field of ADCs is expe\u00adri\u00aden\u00adcing. The capi\u00adtal gained will enable us to further advance the plat\u00adforms and deve\u00adlop our first two selec\u00adted ADC candi\u00adda\u00adtes towards the clinic,\u201d said Domi\u00adnik Schu\u00adma\u00adcher, CEO and co-foun\u00adder of Tubu\u00adlis (photo: right,<\/strong> next to co-foun\u00adder Dr. Jonas Helma-Smets).<\/p>\n

\u201cTubu\u00adlis is directly addres\u00adsing the current limi\u00adta\u00adti\u00adons in ADCs and actively shaping the future of ADC thera\u00adpeu\u00adtics for the treat\u00adment of a variety of diffe\u00adrent dise\u00ada\u00adses. We look forward to support\u00ading the Tubu\u00adlis team as they build their busi\u00adness in this rapidly growing area that is in dire need of inno\u00adva\u00adtive solu\u00adti\u00adons,\u201d Michael Wacker, Part\u00adner at BioMedPartners<\/p>\n

Tubu\u00adlis\u2019 unique and versa\u00adtile ADC port\u00adfo\u00adlio consists of two proprie\u00adtary tech\u00adno\u00adlo\u00adgies. These are based on scien\u00adti\u00adfic results from the rese\u00adarch groups of Prof. Chris\u00adtian Hacken\u00adber\u00adger (FMP), Prof. Hein\u00adrich Leon\u00adhardt (LMU) and Dr. Jonas Helma-Smets, who are all co-foun\u00adders of the company. Further\u00admore, Jonas Helma-Smets serves as CSO of the company.<\/p>\n

Both plat\u00adforms address the comple\u00adxity of modern ADC design in terms of protein format, drug potency, and drug hydro\u00adpho\u00adbicity. P5 conju\u00adga\u00adtion is a novel tech\u00adno\u00adlogy for cysteine-selec\u00adtive conju\u00adga\u00adti\u00adons. It allows the deve\u00adlo\u00adp\u00adment of parti\u00adcu\u00adlarly stable ADCs with unpre\u00adce\u00adden\u00adted linker stabi\u00adlity and chemi\u00adcal flexi\u00adbi\u00adlity. This enables rapid iden\u00adti\u00adfi\u00adca\u00adtion of poten\u00adtial deve\u00adlo\u00adp\u00adment candi\u00adda\u00adtes. The Tub-tag\u00ae plat\u00adform is inspi\u00adred by the biology of micro\u00adtu\u00adbu\u00adles. The Tub-tag\u00ae modi\u00adfi\u00adca\u00adtion of the anti\u00adbody crea\u00adtes a favorable microen\u00advi\u00adron\u00adment for the coupling of the most chal\u00adlen\u00adging drugs. In addi\u00adtion, the Tub-tag\u00ae deri\u00adved from the human system redu\u00adces the risk of adverse immune reac\u00adtions. The combi\u00adna\u00adtion of these plat\u00adforms addres\u00adses the key chal\u00adlenges in the field, ADC stabi\u00adlity as well as drug-deri\u00adved toxicity.<\/p>\n

Tubu\u00adlis intends to prefe\u00adren\u00adti\u00adally use these tech\u00adno\u00adlo\u00adgies for inter\u00adnal drug iden\u00adti\u00adfi\u00adca\u00adtion and deve\u00adlo\u00adp\u00adment, with the goal of gene\u00adra\u00adting novel ADCs that deeply inter\u00adfere with the biology of the respec\u00adtive indication.During the spin-off phase, the company has alre\u00adady been awarded seve\u00adral start-up prizes. These include the Venture.Med 2019 \u201cOutstan\u00adding Start-up Award,\u201d the \u201cLeib\u00adniz Entre\u00adpre\u00adneur\u00adship Award,\u201d and being named an offi\u00adcial \u201cEIT Health Success Story.\u201d Further\u00admore, Tubu\u00adlis is a company supported by the EIT Health Inves\u00adtor Network.<\/p>\n

About Tubu\u00adlis<\/strong>
\nTubu\u00adlis uses proprie\u00adtary tech\u00adno\u00adlo\u00adgies to deve\u00adlop novel drugs whose mecha\u00adnisms of action go deep at the root cause of the dise\u00adase in ques\u00adtion. Our goal is to expand the thera\u00adpeu\u00adtic poten\u00adtial of so-called Anti\u00adbody Drug Conju\u00adga\u00adtes (ADCs). We want to usher in a new era in this product class and ther\u00adeby achieve better results for pati\u00adents. With our proprie\u00adtary deve\u00adlo\u00adp\u00adment approach to ADCs, Tubu\u00adlis will advance a number of product candi\u00adda\u00adtes that can be used for multi\u00adple indi\u00adca\u00adti\u00adons. For more infor\u00adma\u00adtion, visit www.tubulis.com or follow us on Linke\u00addIn and Twit\u00adter. www.tubulis.com<\/p>\n

About BioMed\u00adPart\u00adners<\/strong>
\nBioMed\u00adPart\u00adners is an inde\u00adpen\u00addent Euro\u00adpean venture capi\u00adtal firm based in Basel. It acts as a lead or co-lead inves\u00adtor, provi\u00adding private capi\u00adtal to early to mid-stage life science compa\u00adnies. Since 2002, BioMed\u00adPart\u00adners has inves\u00adted in seve\u00adral highly inno\u00adva\u00adtive compa\u00adnies, 22 of which have alre\u00adady been successfully acqui\u00adred by leading biopharma compa\u00adnies or have comple\u00adted an IPO. BioMed\u00adPart\u00adners has more than CHF 350 million in capi\u00adtal available and has estab\u00adlished itself as one of the leading early-stage health\u00adcare inves\u00adtors in Europe with a strong team of expe\u00adri\u00aden\u00adced indus\u00adtry experts and an exten\u00adsive network in science and pharma.<\/p>\n

In Febru\u00adary 2018, the company announ\u00adced the closing of BioMed\u00adIn\u00advest III, its third equity and corpo\u00adrate capi\u00adtal fund of over CHF 100 million. In this third fund, BioMed\u00adPart\u00adners focu\u00adses on support\u00ading compa\u00adnies with highly inno\u00adva\u00adtive early-stage tech\u00adno\u00adlogy plat\u00adforms. One of BioMed\u00adIn\u00advest III\u2019s first invest\u00adments was the Swiss immuno-onco\u00adlogy company Amal SA (Geneva), which was acqui\u00adred by B\u00f6hrin\u00adger Ingel\u00adheim in June 2019. www.biomedvc.com.<\/p>\n

About Seven\u00adture Partners<\/strong>
\nWith \u20ac750m net commit\u00adments under manage\u00adment as of the end of 2018, Seven\u00adture Part\u00adners is a leading venture capi\u00adtal firm in Europe. Since 1997, Seven\u00adture Part\u00adners has been inves\u00adt\u00ading in inno\u00adva\u00adtive busi\u00adnesses with high growth poten\u00adtial in two fields: Life scien\u00adces across Europe, Israel, Asia and North America and Digi\u00adtal tech\u00adno\u00adlo\u00adgies in France and Germany. In Life scien\u00adces, the main areas of focus include \u201cclas\u00adsic\u201d approa\u00adches such as biotech\u00adno\u00adlogy and phar\u00admaceu\u00adti\u00adcals, diagno\u00adstic and medtech, indus\u00adtrial biotech\u00adno\u00adlogy, as well as \u201cbeyond the pill\u201d approa\u00adches such as MICRO\u00adBIOME-linked inno\u00adva\u00adtions, nutri\u00adtion, food\u00adtech, digital\/connected health and perso\u00adna\u00adli\u00adzed medi\u00adcine. www.seventure.fr\/en<\/p>\n

About copa\u00adrion<\/strong>
\ncopa\u00adrion is a venture capi\u00adtal inves\u00adtor for young, German tech\u00adno\u00adlogy compa\u00adnies. With a fund volume of 275 million euros, copa\u00adrion is making a signi\u00adfi\u00adcant contri\u00adbu\u00adtion to rapid and sustainable growth. copa\u00adrion supports entre\u00adpre\u00adneu\u00adrial vision with know-how without inter\u00adfe\u00adring in the opera\u00adtio\u00adnal busi\u00adness. With many years of expe\u00adri\u00adence in venture capi\u00adtal and in buil\u00adding up compa\u00adnies, the copa\u00adrion team reco\u00adgni\u00adzes poten\u00adtial and opens up new perspec\u00adti\u00adves. copa\u00adrion finan\u00adces exclu\u00adsi\u00advely toge\u00adther with co-inves\u00adtors. The focus is on the startup and young growth phase. The fund invests up to 10 million euros per company, usually in seve\u00adral finan\u00adcing rounds of 1\u20135 million euros each. copa\u00adrion has offices in Colo\u00adgne and Berlin. www.coparion.vc<\/p>\n

About Bayern Kapital<\/strong>
\nBayern Kapi\u00adtal GmbH, based in Lands\u00adhut, was foun\u00added in 1995 as a wholly owned subsi\u00addiary of LfA F\u00f6rder\u00adbank Bayern on the initia\u00adtive of the Bava\u00adrian state govern\u00adment. As the venture capi\u00adtal company of the Free State of Bava\u00adria, Bayern Kapi\u00adtal provi\u00addes equity capi\u00adtal to the foun\u00adders of inno\u00adva\u00adtive high-tech compa\u00adnies and young, inno\u00adva\u00adtive tech\u00adno\u00adlogy compa\u00adnies in Bava\u00adria. Bayern Kapi\u00adtal curr\u00adently mana\u00adges thir\u00adteen invest\u00adment funds with an invest\u00adment volume of around 500 million euros. To date, Bayern Kapi\u00adtal has inves\u00adted around 330 million euros of venture capi\u00adtal in around 280 inno\u00adva\u00adtive tech\u00adno\u00adlogy-orien\u00adted compa\u00adnies from a wide range of sectors, inclu\u00adding life scien\u00adces, soft\u00adware & IT, mate\u00adri\u00adals & new mate\u00adri\u00adals, nano\u00adtech\u00adno\u00adlogy and envi\u00adron\u00admen\u00adtal tech\u00adno\u00adlogy. www.bayernkapital.de<\/p>\n

About OCCIDENT<\/strong>
\nOCCIDENT is an inter\u00adna\u00adtio\u00adnal venture capi\u00adtal inves\u00adtor with offices in Zug and Munich, is owner-mana\u00adged and invests its own assets. The claim is to make a posi\u00adtive contri\u00adbu\u00adtion to society through sustainable and meaningful investments.<\/p>\n

OCCIDENT invests in inno\u00adva\u00adtive deep tech start\u00adups with excel\u00adlent tech\u00adno\u00adlo\u00adgies from the life\u00adsci\u00aden\u00adces, digi\u00adtal and high-tech sectors with broad appli\u00adca\u00adti\u00adons and the poten\u00adtial for value-gene\u00adra\u00adting further deve\u00adlo\u00adp\u00adment. The geogra\u00adphi\u00adcal invest\u00adment focus is Germany and Switz\u00ader\u00adland. Initial finan\u00adcing is prefer\u00ada\u00adbly from seed finan\u00adcing round or later and from 0.5 million euros. OCCIDENT is charac\u00adte\u00adri\u00adzed in parti\u00adcu\u00adlar by its profound under\u00adstan\u00adding of tech\u00adno\u00adlogy and the versa\u00adtile support of its port\u00adfo\u00adlio compa\u00adnies by a compe\u00adtent team of experts. For more infor\u00adma\u00adtion, please visit www.occident.group.<\/p>\n

About High-Tech Gr\u00fcnderfonds<\/strong>
\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start-ups with growth poten\u00adtial. With a volume of around EUR 900 million spread across three funds and an inter\u00adna\u00adtio\u00adnal part\u00adner network, HTGF has supported almost 600 start-ups since 2005. His team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and start-up experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups from the fields of digi\u00adtal busi\u00adness models, indus\u00adtrial tech, life scien\u00adces, chemis\u00adtry and rela\u00adted busi\u00adness areas. More than \u20ac2.5 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in more than 1,600 follow-on finan\u00adcing rounds to date. In addi\u00adtion, the fund has alre\u00adady successfully sold shares in more than 100 companies.<\/p>\n","protected":false},"excerpt":{"rendered":"

Munich, Germany \u2014 Tubu\u00adlis today announ\u00adced the closing of a \u20ac10.7 million Series A finan\u00adcing round. This is inten\u00added to drive the deve\u00adlo\u00adp\u00adment of a new class of highly stable and potent Anti\u00adbody Drug Conju\u00adga\u00adtes (ADCs, \u201canti\u00ad\u00adbody-drug conju\u00adga\u00adtes\u201d) and to support the further growth of the company. Tubu\u00adlis closes \u20ac10.7M Series A finan\u00adcing was led [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":35079,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1373],"tags":[],"class_list":["post-43315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\nTubulis: \u20ac10.7 million Series A financing from prominent investors - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tubulis: \u20ac10.7 million Series A financing from prominent investors - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Munich, Germany \u2014 Tubu\u00adlis today announ\u00adced the closing of a \u20ac10.7 million Series A finan\u00adcing round. This is inten\u00added to drive the deve\u00adlo\u00adp\u00adment of a new class of highly stable and potent Anti\u00adbody Drug Conju\u00adga\u00adtes (ADCs, \u201canti\u00adbody-drug conju\u00adga\u00adtes\u201d) and to support the further growth of the company. Tubu\u00adlis closes \u20ac10.7M Series A finan\u00adcing was led […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-21T20:10:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"337\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Tubulis: \u20ac10.7 million Series A financing from prominent investors\",\"datePublished\":\"2020-07-21T20:10:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\"},\"wordCount\":1322,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Investors\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\",\"url\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\",\"name\":\"Tubulis: \u20ac10.7 million Series A financing from prominent investors - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg\",\"datePublished\":\"2020-07-21T20:10:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg\",\"width\":600,\"height\":337},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis: \u20ac10.7 million Series A financing from prominent investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubulis: \u20ac10.7 million Series A financing from prominent investors - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/","og_locale":"en_US","og_type":"article","og_title":"Tubulis: \u20ac10.7 million Series A financing from prominent investors - FYB Financial Yearbook","og_description":"Munich, Germany \u2014 Tubu\u00adlis today announ\u00adced the closing of a \u20ac10.7 million Series A finan\u00adcing round. This is inten\u00added to drive the deve\u00adlo\u00adp\u00adment of a new class of highly stable and potent Anti\u00adbody Drug Conju\u00adga\u00adtes (ADCs, \u201canti\u00adbody-drug conju\u00adga\u00adtes\u201d) and to support the further growth of the company. Tubu\u00adlis closes \u20ac10.7M Series A finan\u00adcing was led […]","og_url":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2020-07-21T20:10:47+00:00","og_image":[{"width":600,"height":337,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Tubulis: \u20ac10.7 million Series A financing from prominent investors","datePublished":"2020-07-21T20:10:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/"},"wordCount":1322,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg","articleSection":["General","Featured","News","Investors","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/","url":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/","name":"Tubulis: \u20ac10.7 million Series A financing from prominent investors - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg","datePublished":"2020-07-21T20:10:47+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/07\/a-tubulis.jpg","width":600,"height":337},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/tubulis-e10-7-million-series-a-financing-from-prominent-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Tubulis: \u20ac10.7 million Series A financing from prominent investors"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43315"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43315\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/35079"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}